Your activity: 2 p.v.
< Back

Assessment and management of depression in palliative care

Assessment and management of depression in palliative care
Authors:
William Breitbart, MD
Anna L Dickerman, MD
Section Editors:
Susan D Block, MD
Peter P Roy-Byrne, MD
Deputy Editors:
Jane Givens, MD, MSCE
David Solomon, MD
Literature review current through: Dec 2022. | This topic last updated: Jul 25, 2022.

INTRODUCTION — Patients with advanced illness often experience psychological distress. While emotional distress is natural and expected in individuals experiencing serious illness and confronting the end of their lives, the differentiation between a normal and appropriate reaction to dying versus a more serious psychiatric disorder such as major depression can be clinically challenging.

This topic reviews assessment and management of depression in patients receiving palliative care for serious illness. The basic principles of palliative care, assessment and management of other symptoms that are prevalent among patients with advanced illness, and psychosocial, existential, and spiritual issues in palliative care are discussed separately. (See "Benefits, services, and models of subspecialty palliative care" and "Overview of comprehensive patient assessment in palliative care" and "Approach to symptom assessment in palliative care" and "Overview of managing common non-pain symptoms in palliative care" and "Psychosocial issues in advanced illness" and "Overview of spirituality in palliative care".)

SCOPE OF THE PROBLEM — Depressive syndromes are a common mental health problem in palliative medicine, yet they are widely misunderstood, underdiagnosed, and undertreated [1-5]. Data on the prevalence of moderate to severe depression in the last six months of life for patients with terminal cancer were provided by a unique observational cohort study of all cancer decedents in Ontario Canada between 2007 and 2009 (figure 1) [6].

Clinicians often fail to recognize the extent of a patient's depression until too late in the course of the disease. As an example, in a survey of 1046 consecutive hospice patients, only 10 percent were prescribed antidepressants at some point during hospice care [3]. Patients prescribed tricyclic antidepressants were nearly always underdosed, and three-fourths of those started on antidepressants died within two weeks.

Among the many barriers to the recognition and treatment of psychological symptoms in patients with advanced illness are the following:

●The mistaken belief that all patients facing or contemplating the end of life are "depressed"

●The clinician's lack of knowledge and skill at recognizing and treating major depression [7]

●Fear of upsetting the patient or intruding at an emotionally vulnerable time

●The stigma associated with psychiatric diagnoses such as major depression

●Apprehension about possible drug-drug interactions with psychotropic agents

●When caring for patients with advanced illness, clinicians themselves may feel a sense of hopelessness that can lead to therapeutic nihilism [8]

Burden of depression — Psychological distress is a major cause of suffering among patients with advanced disease or terminal illness [9,10]. Depressive syndromes are highly correlated with a reduced quality of life, greater difficulty in managing the course of the patient's illness, decreased adherence to treatment, and earlier admission to inpatient or hospice care [1,11-16]. Depression also impairs the patient's capacity for pleasure, meaning, connection, and doing the emotional work of separating and saying goodbye; it amplifies pain and other symptoms, and causes anguish and worry in family members and friends [8].

Depression, suicide, and desire for a hastened death — Individuals with advanced illness who suffer from depressive syndromes are also at high risk of suicide and suicidal ideation, and they have an increased desire for a hastened death [4,17-23]. (See "Suicidal ideation and behavior in adults".)

●One study concluded that suicidal ideation was relatively infrequent in cancer and limited to those who were significantly depressed [22].

●In a review of psychiatric consultation data from Memorial Sloan-Kettering Cancer Center, one-third of suicidal cancer patients had major depression, and 50 percent were diagnosed with an adjustment disorder with features of both anxiety and depression at the time of evaluation [21,24].

●Although some studies suggest that hopelessness is a significantly better predictor of completed suicide than is depression alone [25-27], others have found that a clinical diagnosis of depression, the severity of depressive symptoms, and a sense of hopelessness are all strong and independent predictors of a desire for hastened death in the terminally ill [20,28]. Depression, hopelessness, and general psychological distress are also consistently associated with interest in physician-assisted dying and euthanasia; as many as 59 percent of patients requesting physician-assisted dying are depressed [29].

Prevalence of depression in palliative care — The prevalence of depressive syndromes in patients with advanced or terminal illness varies widely.

Cancer patients — The reported prevalence of major depression in individuals with cancer varies from 3 to 38 percent [30-36]. This wide variability is explained by the lack of agreement as to appropriate diagnostic criteria to be used in the setting of advanced illness (table 1), differences in patient populations (ie, demographics, type and stage of disease, treatment versus no treatment), and variation in assessment methods. In general, rates are higher in populations with advanced cancer, greater levels of disability, and/or unrelieved pain [33,35,37-39]. (See 'Assessment and diagnosis' below.)

Even when the most stringent criteria are used, major depression is diagnosed in approximately 7 percent, and minor depression in 11 percent, of patients with advanced cancer [33,38-40]. The reported prevalence of depression in terminally ill cancer patients is between 13 and 26 percent [12,20,41,42]. These rates are significantly higher than one-month prevalence rates of depression in the general North American population, which range from 1.6 to 4.9 percent [30,31]. (See "Clinical features and diagnosis of psychiatric disorders in patients with cancer: Overview", section on 'Prevalence of psychiatric comorbidity'.)

The clinical features, prevalence, and diagnosis of depressive disorders in patients with cancer are discussed in more detail elsewhere. (See "Clinical features and diagnosis of psychiatric disorders in patients with cancer: Overview".)

Non-cancer populations — Similarly, patients with other advanced medical illnesses also appear to have elevated rates of depression. Within non-cancer populations, depression has been identified in up to 27 percent of patients with end-stage kidney disease and those seeking to discontinue dialysis [43,44], 20 to 40 percent of those with Parkinson disease [45,46], 35 percent of patients with advanced multiple sclerosis [47], and 22 to 46 percent of patients with advanced heart failure [48,49]. Depression is also a common symptom in patients with AIDS, affecting 23 to 52 percent of those with end-stage disease [50,51]. (See "Depression, mania, and schizophrenia in HIV-infected patients" and "Kidney palliative care: Principles, benefits, and core components".)

Risk factors — An awareness of the specific risk factors for depressive disorders in patients receiving end-of-life care may facilitate early diagnosis and intervention [52].

Age and gender — In several (but not all [53]) studies, younger cancer patients have higher rates of depressive disorders and self-reported distress [54-58]. While depression is twice as common in women as compared with men in the general population, gender is not consistently reported to be a risk factor for depression in cancer patients [33,59].

Prior history of depression — A past history of depression is a risk factor for major depression in cancer patients [5,60].

Uncontrolled symptoms — The presence of uncontrolled symptoms, particularly pain, is a major risk factor for depression and suicide among patients with cancer [61-63]. Some speculate that depression may result in an amplification of pain, while others suggest that it lessens the ability to tolerate the stress of physical symptoms [64,65]. Thus, the causal pathway may be bidirectional [66].

Type of illness — The incidence of depression also depends upon the patient's particular illness. Among cancer patients, those with head and neck and pancreatic cancers are at a particularly high risk [33,67]. For patients with pancreatic cancer, psychiatric symptoms may precede the physical symptoms of the disease by several months, leading some to propose that tumor-induced changes in the neuroendocrine system may contribute to depression [61,67,68].

Illness and treatment-related factors — Certain factors associated with the patient's illness or its treatment may be associated with depression. Tumors arising within or metastasizing to the central nervous system can cause depression [15,58,69,70]. In the case of pituitary tumors, this may be related to excess cortisol production [71-73]. Metabolic complications such as hypercalcemia, often associated with breast and lung cancers, can also be associated with depression. (See "Clinical manifestations of hypercalcemia".)

Depression is common among patients with HIV/AIDS. HIV infection increases the risk of depression both through direct damage to subcortical brain areas and by disease-related chronic stress, social isolation, and intense demoralization. (See "Overview of the neuropsychiatric aspects of HIV infection and AIDS", section on 'Major Depression'.)

Other causes of depression in cancer patients include toxins created by a tumor, possibly autoimmune reactions [74], viral infections, and nutritional deficiencies. Depression can also represent an adverse effect from certain treatments, including glucocorticoids; chemotherapy drugs (vincristine, vinblastine, asparaginase, intrathecal methotrexate, interferon, and tamoxifen [75-82]); as well as radiotherapy to the brain or head and neck [83-87]. (See "Major side effects of systemic glucocorticoids".)

Existential concerns and spirituality — The recognition of a life-threatening crisis brings existential concerns (unfulfilled ambitions, the meaning of life, maintaining dignity at the end of life) to the forefront [1]. Existential suffering and deep personal anguish are some of the most distressing experiences that occur in the dying [88]. The relationship between existential distress and depressive syndromes among the terminally ill is not well studied. In one study, existential distress (ie, concerns related to loss of meaning in life) showed a higher correlation with scores on depression scales than did items pertaining to physical symptoms, medical treatment, or social isolation [57].

Patients who have high levels of spiritual wellbeing tend to be less depressed. The inverse correlation between religious beliefs/spirituality and severity of depressive symptoms was shown in a sample of 162 terminally ill patients with cancer and AIDS [89]. The beneficial aspects of religion related primarily to spiritual wellbeing rather than to formal religious practice. (See "Psychosocial issues in advanced illness" and "Overview of spirituality in palliative care".)

ASSESSMENT AND DIAGNOSIS — Screening for depression should be carried out in all palliative care patients given the high prevalence of symptoms. For patients with cancer, the American Society of Clinical Oncology has issued recommendations for the assessment and diagnosis of depression, endorsing practice guidelines from the Pan-Canadian Guideline on Screening, Assessment and Care of Psychosocial Distress (Depression, Anxiety) in Adults with Cancer [90]. The recommendations state that every patient with cancer should be screened for depression when the initial diagnosis of cancer is made and periodically thereafter as clinically indicated, especially with changes in cancer or treatment status (eg, posttreatment, recurrence, or progression) as well as transition to palliative care. We agree with this recommendation.

The two-item Patient Health Questionnaire (PHQ-2) (table 2) can be used to screen for depression. Patients who screen positive (a single "yes" response) should be interviewed to diagnose depression; the interview can be facilitated with the PHQ-9 (table 3). Additional information about screening for depression is discussed separately. (See "Screening for depression in adults".)

Depressed mood, sadness, grief, and anticipatory feelings of loss are all appropriate responses to advanced disease and dying. However, feelings of hopelessness, helplessness, worthlessness, guilt, lack of pleasure, and suicidal ideation (even mild or passive) are among the best indicators of depressive syndromes in these patients [21,24,91]. Passive suicidal ideation ("I'd be better off dead") should be distinguished from active suicidal ideation ("I’m going to kill myself"). (See "Bereavement and grief in adults: Clinical features", section on 'Unipolar major depression'.)

A summary of some of the contrasting characteristics of normal grief versus depression in terminally ill patients is provided in a table (table 4) [8].

There are two important caveats:

●Feelings of hopelessness, helplessness, and guilt must be considered in the context of the patient's illness. Hopelessness may be difficult to interpret in the setting of a disease where there is no hope for cure or recovery [27]. Furthermore, patients may feel helpless because of their physical condition, or there may be a sense of guilt if the illness is related to certain behaviors (eg, cirrhosis and hepatocellular cancer in alcoholics, lung cancer in smokers). Symptoms that seem out of proportion to the patient's actual situation should prompt concern for major depression.

●There is considerable overlap between the neurovegetative or somatic symptoms of major depression (eg, fatigue, insomnia, anorexia, and weight loss) and those associated with any serious illness and/or its treatment. This has led some to exclude these symptoms from diagnostic criteria for depression in medically ill patients, a subject that is discussed in detail below. (See 'Criterion-based diagnosis' below.)

Tools for assessment and diagnosis — There are two major types of research methods that are available for the assessment of depression in advanced illness: criterion-based instruments, which may be based upon a diagnostic classification scheme or the outcome of a structured diagnostic interview, and self-report measures. The available tools are summarized in a table (table 5).

Criterion-based diagnosis — The most widely used criteria to diagnose depression in non-terminally ill patients are those outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [92]. If sufficient criteria are not met for the diagnosis of major depression, then patients may be classified as "adjustment disorder" with depressive features, or mood disorder secondary to medical condition.

Small differences between investigators in the application of symptom severity thresholds (eg, the severity with which symptoms must be expressed before they are considered clinically significant) can result in large differences in prevalence rates for depression in studied populations. Furthermore, as noted previously, because somatic complaints in medically ill patients may also be attributable to the physical effects of the illness or its treatment, their use as diagnostic criteria can also affect the rate of diagnosis of major depression in medically ill patients, particularly when they are used in conjunction with a low-threshold symptom severity approach [32].

Because of these issues, several general approaches to the diagnosis of major depression in the medically ill have evolved, which differ in how they deal with somatic symptoms and in the definition of symptom severity. These approaches are outlined in a table (table 1).

The most widely used is the substitutive approach of Endicott [93]. The Endicott scale replaces four of the DSM-IV-TR somatic criteria thought most likely attributable to medical illness or its treatment (ie, change of weight/appetite, sleep disturbance, loss of energy/fatigue, difficulty thinking or concentrating) with cognitive substitutes (depressed appearance, social withdrawal, brooding/self-pity/pessimism, and lack of reactivity in situations that would normally be pleasurable) (table 6).

Although the substitutive approach is used most often for research purposes, most experts agree that for clinical purposes, the use of a modified inclusive set of diagnostic criteria that incorporates both neurovegetative and psychological symptoms of depression, and emphasizes the presence of hopelessness, worthlessness, guilt, and suicidal ideation is most appropriate for the palliative care population [1,94].

Self-report instruments — Criterion-based diagnostic systems require an in-depth clinical interview. Self-report methods (eg, the PHQ-9 (table 3) [95,96], 21-item Beck Depression Inventory [BDI] or the shorter 13-item scale [97,98], or visual analog scales [99,100]) may be used if a direct face-to-face interview is not feasible. However, these self-report scales are only a crude substitute for a careful diagnostic interview. The efficacy of these tools as a diagnostic aid in the palliative care setting is not as good as a brief interview directly addressing the commonly accepted diagnostic criteria. Situations where they might be useful include providing additional information in difficult cases, quantifying the severity of a depressive syndrome after initial diagnosis, or monitoring changes in depression over time.

A self-report measure designed to differentiate between preparatory grief and depression in adults, the Terminally Ill Grief or Depression Scale (TIGDS), has been developed and validated in a small series of 47 adult inpatients [101]. The tool is comprised of grief and depression subscales totaling 47 questions and is described as easy to administer and acceptable to patients. However, the TIGDS has not been tested in other clinical settings and requires validation in larger samples.

Simple screening instruments — A careful diagnostic interview remains the gold standard method for assessment of depression in medically ill patients [8]. However, direct face-to-face interviews are time-consuming, thus limiting their usefulness in palliative care settings.

More than 50 questionnaires have been developed to aid the detection of depression or severe distress, but most have been validated in primary care patients. Few have been studied specifically in palliative care settings [102-104], and most of these are too long for routine use. Assessment of depression in advanced illness requires instruments that are not only valid and reliable but also minimally burdensome, acceptable to patients, and easy to administer and score. A detailed discussion of depression assessment in cancer patients is provided elsewhere. (See "Clinical features and diagnosis of psychiatric disorders in patients with cancer: Overview", section on 'Assessment of psychiatric symptoms' and "Clinical features and diagnosis of psychiatric disorders in patients with cancer: Overview", section on 'Depressive disorders'.)

Simple one- or two-question and other abbreviated assessments appear to be as effective as longer instruments in screening for depression in most (table 7) [97,99,105-111] but not all studies [112]. The single-item screen is adapted from the Schedule for Affective Disorders and Schizophrenia (SADS) depression criteria [105] and consists simply of asking the question: "Have you been depressed most of the time for the past two weeks?"

This method appears to be accurate for identifying patients who might qualify for a diagnosis of depression on the basis of a full interview covering all of the criterion symptoms, and thus is a useful screening tool to select patients who need further evaluation [97-99,102,106,107,113,114].

The utility of this approach was shown in a study of 200 palliative care in patients with terminal cancer that compared the performance of four brief screen measures for depression, including the single-item question "Are you depressed?", a two-item question assessing depressed mood and loss of interest or pleasure in activities, a visual analog scale (VAS) for mood based on the Memorial Pain Assessment Card [107], and the BDI short version [99]. Using a semi-structured diagnostic interview as the gold standard for diagnosis, the single-item interview (using a threshold stringency equivalent to patients feeling depressed "most of the time") outperformed both the BDI and the VAS. The two-item scale did not identify more depressed patients, and it characterized four patients as being depressed who were classified as not depressed after the full interview.

The sensitivity and specificity of a single-item question as a screen for depression have been shown by others in diverse cohorts [102,113,114], although conflicting results have been observed in palliative care populations in the United Kingdom [104,112,115] and in Japan [116]. This is perhaps not surprising. While some patients may readily verbalize that they are depressed, others, no matter how despairing, may never acknowledge it or may label it something else (eg, nervousness) [94].

Guidelines for distress management from the National Comprehensive Cancer Network (NCCN) suggest the use of a VAS (ranging from no distress to extreme distress) as well as patient self-report of depression, sadness, and loss of interest in usual activities (yes or no) as a screen for depression [117]. Both methods are reasonable as screening tools.

TREATMENT — Major depression in palliative care or terminally ill patients is treatable, although some data suggest that these patients may not be adequately managed. For example, one cross-sectional analysis of patients with cancer with depression (n = 1538) being treated in Scotland found that over 70 percent of those with depression were not receiving potentially effective therapy [118].

The more favorable side effect profile of newer antidepressants (eg, selective serotonin reuptake inhibitors [SSRIs] and serotonin-norepinephrine reuptake inhibitors [SNRIs]) has facilitated their use in older adults and the medically ill. Because treatment with these agents is relatively benign and well tolerated, clinicians should have a low threshold for initiating therapy. Psychostimulants, in comparison with other antidepressants, have a faster onset of activity and are the preferred initial option for palliative care patients whose life expectancy is less than two to four months or for those in need of urgent treatment.

General treatment principles — The first step in treating depression is to relieve uncontrolled symptoms, particularly pain. Although pain is most often an issue in the setting of cancer, patients who have diseases that are not usually considered painful (eg, cardiac disease) may also experience moderate to severe pain at the end of life [119]. (See "Assessment of cancer pain".)

All patients should have a complete medical evaluation to assess possible general medical contributors to depressed mood. (See 'Illness and treatment-related factors' above.)

If depression persists once pain is controlled, and a potentially reversible general medical cause of depressed mood cannot be identified, specific therapy is warranted. Treatment should be tailored to the individual needs of the patient. In addition to drug therapy, effective psychosocial interventions include individual or group psychotherapy, hypnotherapy, cognitive-behavioral therapy (eg, relaxation training and biofeedback), existential therapy, and self-help groups [120-124]. (See "Complementary and alternative therapies for cancer".)

There are no randomized trials that specifically address the benefit of psychotherapy for palliative care patients with depression, and there are few that address pharmacologic treatment [125]. As a result, therapy for depression in these patients is generally based upon the larger body of evidence on effective treatments in patients with cancer, or primary care populations with either no physical illness or less severe medical conditions. Although there is a lack of controlled trials to support the efficacy of combined therapy, most experts recommend an approach that combines supportive psychotherapy with patient and family education and judicious use of antidepressant medication [8]. (See "Management of psychiatric disorders in patients with cancer" and "Unipolar major depression in adults: Choosing initial treatment" and "Unipolar depression in adults: Supportive psychotherapy".)

It is important to note that for patients in palliative care, the data support the use of integrated treatment delivered collaboratively between disease-specific specialists, primary care providers, and mental health specialists. While best studied in patients with cancer [126], it is likely that patients with other life-threatening illnesses may derive a similar benefit.

Psychosocial interventions — A broad range of psychological interventions have been found to be effective for the treatment of major depression in a variety of patients, including those with cancer [127-131]. (See "Management of psychiatric disorders in patients with cancer", section on 'Psychosocial interventions' and "Overview of psychotherapies".)

Psychotherapy increases the effectiveness of drug therapy for major depression in older primary care patients [132,133], and most experts recommend a combined approach in medically ill patients as well, despite the lack of evidence from randomized trials to support this practice. However, patients with severe depressive symptoms may be too immobilized and/or dysphoric to effectively engage in psychotherapy; such patients may first need to receive appropriate pharmacotherapy.

Supportive psychotherapy — The single most important aspect of psychotherapeutic support for depressed terminally ill patients is the therapeutic alliance between the patient and the primary medical caregiver [134]. Optimally, this relationship will be one of mutual trust, respect, and sensitivity. Maintaining ongoing contact with the patient both ensures that symptoms and treatment efficacy will be continuously reevaluated and reassures the patient that they will not be abandoned throughout the course of the terminal illness.

Supportive psychotherapy aims to support adaptive coping mechanisms, minimize maladaptive ones, and decrease adverse psychological reactions such as fear, shame, self-loathing, and withdrawal. The main components of psychotherapy are active listening, supportive verbal interventions, and occasional interpretation.

Clinicians should elicit from the patient their concerns about death and the dying process but need not focus solely on the issue of death. Patients should be encouraged to talk about their lives and experiences, fears about the impact of illness on family members, and past experiences of coping with loss. Patients should be encouraged to freely talk about or ask questions about their prognosis, with their therapist taking an interested and interactive role in the discussion. Reassurance is useful when it is based on a specific understanding of the individual's status and is not clinically unrealistic.

Supportive therapy can be provided by the primary medical caregiver, psychiatrist, psychologist, hospice nurse, or social worker, depending on time, interest, training, and the severity of the patient's condition. Sometimes, supportive psychotherapy alone is sufficient to treat depression. Treating major depression with supportive psychotherapy is discussed in more detail separately. (See "Unipolar depression in adults: Supportive psychotherapy".)

Structured cognitive therapies — Cognitive-behavioral techniques, which focus on distorted thoughts that adversely affect mood, are often integrated into depression therapy. These approaches explore patients' beliefs about the cancer diagnosis and its treatment and attempt to elicit irrational or unhelpful thoughts that lead to feelings of helplessness and hopelessness. Therapy then leads to the correction of these maladaptive thoughts along with providing new coping skills (eg, relaxation). (See "Management of psychiatric disorders in patients with cancer", section on 'Cognitive-behavioral therapy'.)

Existential psychotherapy — Serious illness has a profound impact on the sense of self; the physical and psychological losses that are often part of the illness challenge one's sense of wholeness and integrity, which are key components of emotional health. Serious illness also challenges personal values of independence and control (which together form the construct of dignity) as well as self-determination and self-worth.

Existential therapies such as dignity therapy [135-139], meaning-centered psychotherapy [140,141], and therapeutic life review [142] may represent appropriate choices for some terminally ill patients who confront daily choices that affect quality of life and who often have questions about the meaning, purpose, and value of their lives. Such therapy can improve spiritual wellbeing, lessen sadness and depression, and sustain or enhance a sense of meaning, peace, and purpose at the end of life. (See "Overview of spirituality in palliative care", section on 'Spiritual distress and existential suffering' and "Psychosocial issues in advanced illness", section on 'Common issues for patients with advanced illness'.)

Pharmacotherapy — As with psychotherapy, there is a general lack of high-quality evidence regarding the effectiveness of antidepressants in patients with major depression who are receiving end-of-life care [124,125]. There are no randomized trials focusing on this population. However, randomized trials and meta-analyses have documented the efficacy of antidepressants in depressed patients with physical illness, including those with "life-threatening" physical illness [143]. Furthermore, a systematic review of antidepressants for treatment of depression in palliative care, which included 25 placebo-controlled randomized trials, demonstrated significant benefit of treatment over placebo within four to five weeks, with continued improvement over time [144]. (See "Management of psychiatric disorders in patients with cancer", section on 'Pharmacotherapy'.)

Drug selection — There are several classes of antidepressants, including:

●Psychostimulants (eg, dextroamphetamine, methylphenidate, and modafinil)

●SSRIs (see "Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects")

●Tricyclic antidepressants (TCAs) and tetracyclic antidepressants (see "Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects")

●SNRIs (see "Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects")

●Serotonin modulators (eg, nefazodone, trazodone, and vilazodone) (see "Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects")

●Atypical antidepressants (eg, agomelatine, bupropion, and mirtazapine) (see "Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects")

●Monoamine oxidase inhibitors (MAOIs), which are rarely used in palliative care (see "Monoamine oxidase inhibitors (MAOIs): Pharmacology, administration, safety, and side effects")

The agents used most commonly in palliative care patients are psychostimulants, SSRIs, and TCAs (table 8). Although there is no evidence that any particular antidepressant or class of antidepressants is preferable for patients receiving end-of-life or palliative care, the 2008 clinical practice guidelines for initial treatment of depression in primary care patients from the American College of Physicians make a strong recommendation to initiate an SSRI, SNRI, or atypical antidepressant [145]. The most compelling reason why SSRIs are usually selected for initial therapy in depressed primary care patients is not because of demonstrated greater efficacy but because of their more favorable side effect profile [146,147] and the markedly lower danger with overdose. (See "Unipolar major depression in adults: Choosing initial treatment" and "Tricyclic antidepressant poisoning".)

However, there is some evidence that TCAs might be preferred for severely depressed patients. In general, patients with severe depression are less likely to drop out of treatment trials because of unacceptable side effects when taking an SSRI as compared with a TCA, but they are more likely to drop out because of treatment inefficacy. Evidence-based European guidelines for management of depression in palliative cancer care do not endorse any one category of antidepressants for initial therapy [148]. (See "Unipolar major depression in adults: Choosing initial treatment", section on 'Selecting a specific antidepressant'.)

In addition to these drugs, psychostimulants are an important option for treatment of depression at the end of life because, unlike classic antidepressants, they take effect quickly.

For palliative care patients, the factors that influence the choice of initial agent in addition to side effect profile (table 9) are the available timeframe for treatment, coexisting medical problems and symptoms, and pharmacologic properties (eg, half-life, potential for drug-drug interactions, and availability of liquid formulation):

●While patients with an anticipated life expectancy of several months can afford to wait one or two weeks for a TCA or SSRI to begin working (as long as immediate onset of action is not essential), those with a shorter remaining lifespan (or severe depression requiring urgent treatment) do better with rapidly acting psychostimulants [149-153]. Psychostimulants can be useful for the treatment of depressive symptoms in patients who are weeks from death. Even patients who are extremely debilitated and fatigued may experience improvement in mood and energy within 24 to 48 hours of starting treatment (table 8).

Psychostimulants may also be useful as initial agents for patients with a relatively long estimated lifespan who have severe depression and require urgent treatment and a rapid response [154]. An antidepressant such as an SSRI can be introduced concurrently and the dose increased to therapeutic levels over one to two weeks while the dose of the psychostimulant is gradually decreased.

●Older adult patients and those with cardiovascular disease should avoid drugs that cause orthostatic hypotension (eg, TCAs) (table 9). Similarly, because they lack anticholinergic effects, SSRIs are preferred for patients with slowed intestinal motility or urinary retention, as well as those who have stomatitis or chronic dry mouth secondary to chemotherapy or radiotherapy.

●For patients who are at risk for seizures or who may have a lower seizure threshold because of other medications, maprotiline (where available) and bupropion should be avoided as they are associated with the highest seizure risk (table 9). However, virtually any antidepressant can have a small effect on lowering the seizure threshold, and all agents should be used cautiously in patients with central nervous system (CNS) disease.

●Side effects may sometimes be used to the patient's advantage. As an example, the depressed patient who is experiencing agitation or insomnia may benefit from the more sedating antidepressants (eg, TCAs, trazodone, or mirtazapine) (table 9). By contrast, patients with fatigue or psychomotor slowing may do better with compounds that have the least sedating effects (eg, SSRIs and psychostimulants).

In addition to their antidepressant action, the TCAs have analgesic properties (as do SNRIs such as venlafaxine and duloxetine), and they potentiate the effects of opioid analgesics. Thus, patients who are experiencing pain, particularly neuropathic pain, may benefit from these agents alone or in combination with other drugs. (See "Cancer pain management: Role of adjuvant analgesics (coanalgesics)", section on 'Antidepressants'.)

●Liquid formulations are available for some antidepressants (eg, fluoxetine, sertraline, paroxetine, citalopram, escitalopram, doxepin, and nortriptyline) and may be preferred for patients who cannot swallow pills.

●Rather than continuously experimenting with a range of different drugs, clinicians should become comfortable with prescribing a single drug from each class in order to become familiar with dosing regimens, actions, interactions, and side effects. Specific interactions of antidepressants with other medications may be determined using the Lexicomp drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on drug interactions.

Selective serotonin reuptake inhibitors — In most cases, SSRIs are preferred for first-line therapy. SSRIs are generally as effective as TCAs for the treatment of depression, and they have a wider margin of safety than TCAs in the event of an overdose.

There are currently several SSRIs marketed in the United States: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline (table 8). All have similar efficacy but differ in pharmacokinetics, drug interactions, and side effect profile. Although SSRIs are generally well tolerated, dose-related side effects such as jitteriness, restlessness, anxiety, agitation, headache, sexual dysfunction, gastrointestinal symptoms (diarrhea and nausea), and insomnia are common and may be problematic in debilitated patients (table 9). Headache and jitteriness often subside after the first four to seven days of antidepressant initiation. (See "Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects".)

Fluoxetine was shown to significantly improve quality of life and depressive symptoms in patients with advanced cancer in two of the only controlled trials carried out in this population [155,156]. However, the clinical use of this agent in palliative care is limited by its long half-life (it takes five to six weeks to reach steady state drug concentrations) and the potential for significant drug-drug interactions because it inhibits hepatic drug metabolizing enzymes such as cytochrome P450 [157,158]. Specific interactions of fluoxetine and other SSRIs with other medications may be determined using the Lexicomp drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on drug interactions. The specific cytochrome enzymes that each SSRI and their metabolites potently or moderately inhibit are summarized elsewhere. (See "Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Drug-drug interactions'.)

In contrast to the long half-life of fluoxetine, steady state levels are reached in 4 to 14 days with paroxetine, fluvoxamine, and sertraline. However, the advantages of a shorter half-life SSRI such as paroxetine and fluvoxamine in ill cancer patients is counterbalanced by the fact that a missed dose may result in fairly rapid and unpleasant withdrawal syndrome. This does not tend to happen with sertraline.

Paroxetine, fluvoxamine, and sertraline are also likely to be better tolerated by terminally ill patients than other SSRIs because they have fewer active metabolites, which can accumulate and cause toxicity. Citalopram and escitalopram have significantly fewer interactions with hepatic metabolizing enzymes than the other SSRIs, making them appealing choices in patients who are on other medications where drug-drug interactions are a concern.

As in older adults, the initial SSRI dose for patients with advanced or end-stage medical illness should be approximately one-half that used in otherwise healthy patients (table 8). (See "Diagnosis and management of late-life unipolar depression".)

Tricyclic antidepressants — Many studies have demonstrated the efficacy of TCAs in depressed, medically ill patients, although none are controlled trials.

Although TCAs are still used in terminally ill cancer patients, they are not as well tolerated as SSRIs because of their sedating and autonomic effects, which can be particularly troublesome for terminally ill patients (table 8). The major side effects are anticholinergic effects, including dry mouth, blurred vision, constipation, urinary retention, tachycardia, orthostatic hypotension, impaired memory, confusion, or delirium (table 9). These adverse effects can be particularly problematic for patients receiving other medications with anticholinergic properties. Such patients are at risk for developing anticholinergic delirium [159]. Desipramine and nortriptyline are less anticholinergic than other tricyclics.

Older adults are particularly susceptible to memory impairment, confusion, and hallucinations. Sedation is a particular problem with the tertiary amine tricyclics (ie, imipramine, amitriptyline, and doxepin), which can exacerbate the sedating effects of other medications [149].

Older patients and those with advanced medical illness have a higher likelihood of drug intolerance and drug-drug interactions. Specific interactions of these agents with other medications may be determined using the Lexicomp drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on drug interactions. (See "Diagnosis and management of late-life unipolar depression".)

If TCAs are chosen as the initial agent for older patients, they should be started at low doses and slowly titrated (table 8). In order to minimize drug toxicity and more carefully guide the drug titration process, TCAs with well-established therapeutic plasma levels and generally better tolerance profiles, such as desipramine and nortriptyline, should be prescribed [160]. (See "Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects".)

Other antidepressants — Venlafaxine is a potent SNRI (table 8). Its use in terminally ill depressed patients has not been studied, but its pharmacokinetic properties and generally well-tolerated side effect profile suggest that it is a potentially useful agent [134]. (See "Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Venlafaxine'.)

Mirtazapine has also been shown to be effective for improving multiple symptoms, depression, and quality of life in patients with advanced cancer, although it is relatively sedating [161,162]. (See "Atypical antidepressants: Pharmacology, administration, and side effects", section on 'Mirtazapine'.)

Similarly, trazodone can be an effective antidepressant, but it is also sedating (table 8). It may be given at low doses to treat depressed cancer patients with insomnia, and it may also be useful for patients who require adjunct analgesic effects in addition to antidepressant effects [134]. Trazodone has also been associated with priapism and should thus be used with caution in male patients [163]. Nefazodone has been associated with liver failure and probably should not be used in this patient population. (See "Serotonin modulators: Pharmacology, administration, and side effects", section on 'Trazodone' and "Cancer pain management: Role of adjuvant analgesics (coanalgesics)", section on 'Antidepressants'.)

Bupropion is not the first drug of choice for the treatment of depression in terminally ill patients, although it may be considered for patients who have a poor response to the trial of other antidepressants (see "Switching antidepressant medications in adults"). The energizing effects of bupropion are similar to the stimulant drugs (table 8) [164,165]. However, it is contraindicated for cancer patients with CNS disorders, due to its association with increased incidence of seizures [166]. (See "Atypical antidepressants: Pharmacology, administration, and side effects", section on 'Bupropion'.)

Heterocyclic antidepressants have side effect profiles similar to those for the TCAs [134]. As noted above, maprotiline (where available) should be avoided in patients with brain tumors and patients susceptible to seizures, as seizure incidence is increased with this medication [167]. Mianserin, a serotonergic antidepressant with adjuvant analgesic properties, is widely used in Europe and Latin America but not available in the United States. It is safe and effective for the treatment of depression in cancer [168].

As a drug class, the MAOIs are generally considered a less desirable alternative for treating depression in the terminally ill, due to the large number of adverse interactions associated with these drugs [149,169]. Thus, MAOIs are generally reserved in this patient population for those who have shown past preferential responses to them for treatment of their depression [134]. (See "Monoamine oxidase inhibitors (MAOIs): Pharmacology, administration, safety, and side effects".)

Although it is not a classic antidepressant, the triazolobenzodiazepine alprazolam is a mildly effective antidepressant as well as an anxiolytic and may be particularly useful in medically ill patients who have mixed symptoms of anxiety and depression [123]. A meta-analysis of randomized trials comparing alprazolam with placebo in patients with major depression (not limited to patients in the palliative care population) found greater symptom response with alprazolam [170].

Psychostimulants — The efficacy of psychostimulants (dextroamphetamine, methylphenidate, and modafinil) for the treatment of depression in medically ill patients is supported by small prospective controlled trials [150,171-174]. The main benefit of these agents over TCAs and SSRIs is their more rapid onset of action (often within 24 to 48 hours). (See 'Drug selection' above.)

Psychostimulants may also be helpful in cases where dysphoric mood is associated with opioid-related sedation, severe psychomotor slowing, and even mild cognitive impairment, because stimulants are often energizing and improve overall performance on neuropsychological testing in the medically ill [172,173,175]. At relatively low doses, these medications also stimulate appetite, promote a sense of wellbeing, and relieve feelings of weakness and fatigue in cancer patients [134]. (See "Prevention and management of side effects in patients receiving opioids for chronic pain", section on 'Somnolence and mental clouding' and "Cancer-related fatigue: Treatment".)

Although generally well tolerated, side effects may include agitation, insomnia (particularly if administered within six to eight hours of bedtime), anxiety, and tremor. Cardiac decompensation can occur in older adult patients and in those with heart disease. Rarely, confusion or delirium may occur in older adults or cognitively impaired individuals.

Side effects are uncommon but include headache, nausea, dry mouth, anorexia, and diarrhea. Modafinil has less sympathomimetic effects than amphetamines and is often a good choice for older patients. However, it has been associated with a mild increase in blood pressure and should be used cautiously in people with a history of arrhythmias or heart disease. (See "Treatment of narcolepsy in adults", section on 'Modafinil'.)

Ketamine — Meta-analyses of randomized trials that compared intravenous ketamine with placebo in physically healthy patients with treatment-resistant depression have found rapid, clinically moderate to large benefits with N-methyl-D-aspartate (NMDA) receptor antagonists, such as ketamine; however, the long-term benefits and risks are unknown. Case reports and one small placebo-controlled trial of intravenous ketamine also suggest that ketamine can rapidly improve depressive symptoms in patients with refractory depression in the setting of a terminal illness, particularly in the setting of chronic pain [176-184]. However, the optimal selection of patients for this approach and the best way in which to administer ketamine in this situation are unclear. (See "Ketamine and esketamine for treating unipolar depression in adults: Administration, efficacy, and adverse effects" and "Cancer pain management: Role of adjuvant analgesics (coanalgesics)", section on 'Ketamine and other NMDA receptor antagonists'.)

Emerging psychopharmacologic interventions

Psilocybin-assisted psychotherapy — Psilocybin is a Schedule I substance used only in research settings and is not approved by the US Food and Drug Administration (FDA) for any indication. Psilocybin safety has been tested over several decades (although it has not been studied in patients with brain cancer, psychotic disorders, or psychotic disorders in first-degree relatives) [185]. The potential effectiveness of psychedelics has been investigated in several studies for cancer-related existential distress [186]. Psilocybin-assisted psychotherapy specifically has been studied in randomized Phase II trials for the treatment of existential distress in patients with life-threatening cancer [187-189] and unipolar major depression [190], and in open trials for demoralized long-term AIDS survivors [191] as well as treatment-resistant depression [192], with promising results [193-196], showing acute and sustained reductions in measures of depression and existential distress while also improving quality-of-life metrics such as psychologic and spiritual wellbeing.

Additional information about treating unipolar major depression with psilocybin is discussed separately in the context of highly resistant depression. (See "Unipolar depression in adults: Management of highly resistant (refractory) depression", section on 'Drug therapies'.)

MDMA-assisted psychotherapy — 3,4-Methylenedioxy​methamphetamine (MDMA) is a Schedule I substance and is only used in the context of research or expanded access (granted for compassionate use) [197]. Recreational use of the substance (also known as ecstasy) has been associated with cardiotoxicity, neurotoxicity, and death [198-200]. Adverse events in clinical trials have typically been transient, mild to moderate in severity, and have included muscle tightness, decreased appetite, nausea, hyperhidrosis, and feeling cold [201]. MDMA-assisted psychotherapy has shown acute and sustained reduction of posttraumatic stress disorder (PTSD) symptoms in a Phase III clinical trial [201], described in detail elsewhere (see "Management of posttraumatic stress disorder in adults", section on 'Medications with limited supporting evidence'). Future directions in palliative care research could include its use for unipolar major depression, PTSD secondary to life-threatening diagnoses, and cancer recurrence fears.

Electroconvulsive therapy — It is rarely necessary to use electroconvulsive therapy (ECT) for medically ill patients who have depression with psychotic features or in whom treatment with antidepressants is either ineffective or poses unacceptable side effects. ECT is safe for use in the medically ill, but its use in patients near the end of life may be inconsistent with the goal of providing noninvasive and nonintrusive comfort care [202]. (See "Unipolar depression in adults: Choosing treatment for resistant depression", section on 'Electroconvulsive therapy'.)

INDICATIONS FOR PSYCHIATRIC REFERRAL — When assessing and treating depression in palliative care patients, several circumstances should prompt referral to a psychiatrist for an in-depth assessment of the patient's judgment, decision-making capacity, and mood. These include:

●Uncertainty as to the psychiatric diagnosis

●History of a major psychiatric disorder

●Patient is suicidal or requesting assisted suicide or euthanasia

●Patient is psychotic (hallucinations, delusions) or delirious

●Patient is unresponsive to therapy with first-line antidepressants

●Significant family conflict interferes with wellbeing, treatment, or decision-making

The approach to terminally ill patients who ask about hastening death is addressed elsewhere. (See "Physician-assisted dying".)

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Palliative care".)

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

●Basics topics (see "Patient education: Medical care during advanced illness (The Basics)" and "Patient education: Advance directives (The Basics)")

SUMMARY AND RECOMMENDATIONS

●Depression is the most common mental health problem encountered in palliative medicine, yet it is widely misunderstood, underdiagnosed, and undertreated. Individuals who suffer from depression are at high risk of suicide and suicidal ideation, and they have an increased desire for a hastened death. Failure to diagnose and treat depression impairs the quality of life of dying patients and adds to their burden of suffering. (See 'Scope of the problem' above.)

●Screening for depression should be carried out in all palliative care patients. Screening is conducted when the initial diagnosis of cancer is made and periodically thereafter as clinically indicated, especially with changes in cancer or treatment status (eg, posttreatment, recurrence, or progression), as well as transition to palliative care. (See 'Assessment and diagnosis' above.)

●Depressed mood, sadness, grief, and anticipatory feelings of loss are appropriate responses in patients with a serious, life-threatening illness. Feelings of hopelessness, helplessness, worthlessness, guilt, and suicidal ideation (even mild or passive) are among the best indicators of depressive disorders in such patients. (See 'Assessment and diagnosis' above.)

●A careful diagnostic interview is the gold standard method for assessing whether patients are clinically depressed. However, a simple single question ("Have you been depressed most of the time for the past two weeks?") and other abbreviated screening methods appear to be as effective as longer instruments in identifying those patients who require further assessment for depression. (See 'Tools for assessment and diagnosis' above.)

●Major depression in terminally ill patients is treatable. The first step in treating depression is to relieve uncontrolled symptoms, particularly pain. (See 'General treatment principles' above.)

●Supportive psychotherapy can be provided by the primary medical caregiver, psychiatrist, psychologist, hospice nurse, or social worker. While supportive therapy may be sufficient to treat depression, most experts recommend an approach that combines supportive psychotherapy with patient and family education and judicious use of antidepressant medication. (See 'Psychosocial interventions' above.)

●Clinicians should have a low threshold to initiate pharmacologic treatment, even if the diagnosis of a depressive syndrome is in question, because both psychostimulants and newer drugs such as selective serotonin receptor inhibitors (SSRIs) are relatively safe, effective, and well tolerated. (See 'Pharmacotherapy' above.)

●For moderately to severely depressed patients who have an estimated life expectancy of at least two to four months, we recommend both pharmacotherapy and psychotherapy (Grade 1A). For patients whose life expectancy is at least two to four months, we typically initiate therapy with an antidepressant and choose an SSRI rather than a tricyclic antidepressant (TCA) because of their wider safety margin. Patients with more acute depressive symptoms may also benefit from use of a psychostimulant. (See 'Drug selection' above and 'Selective serotonin reuptake inhibitors' above.)

●For patients with a shorter life expectancy (less than two to four months), or who need urgent treatment, we suggest a psychostimulant rather than other drugs (Grade 2C). For patients who have an estimated life expectancy of longer than two to four months, an SSRI is then started, and the dose gradually titrated upwards, while the dose of the psychostimulant is gradually reduced. (See 'Drug selection' above.)

●Regardless of the initial agent chosen, the starting dose should be approximately one-half that used in non-terminally ill patients, and then slowly and carefully titrated. During this time, maintaining ongoing contact with the patient both ensures that symptoms and treatment efficacy will be continuously reevaluated, and it reassures the patient that they will not be abandoned throughout the course of the terminal illness. (See 'Supportive psychotherapy' above.)

●Among the indications for referral to a psychiatrist are the following (see 'Indications for psychiatric referral' above):

•Uncertainty as to the psychiatric diagnosis

•History of a major psychiatric disorder

•Patient is suicidal or requesting assisted suicide or euthanasia

•Patient is psychotic (hallucinations, delusions) or delirious

•Patient is unresponsive to therapy with first-line antidepressants

  1. Breitbart W, Bruera E, Chochinov H, Lynch M. Neuropsychiatric syndromes and psychological symptoms in patients with advanced cancer. J Pain Symptom Manage 1995; 10:131.
  2. Sharpe M, Strong V, Allen K, et al. Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. Br J Cancer 2004; 90:314.
  3. Lloyd-Williams M, Friedman T, Rudd N. A survey of antidepressant prescribing in the terminally ill. Palliat Med 1999; 13:243.
  4. O'Mahony S, Goulet J, Kornblith A, et al. Desire for hastened death, cancer pain and depression: report of a longitudinal observational study. J Pain Symptom Manage 2005; 29:446.
  5. Meyer HA, Sinnott C, Seed PT. Depressive symptoms in advanced cancer. Part 2. Depression over time; the role of the palliative care professional. Palliat Med 2003; 17:604.
  6. Seow H, Barbera L, Sutradhar R, et al. Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol 2011; 29:1151.
  7. Passik SD, Dugan W, McDonald MV, et al. Oncologists' recognition of depression in their patients with cancer. J Clin Oncol 1998; 16:1594.
  8. Block SD. Assessing and managing depression in the terminally ill patient. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians - American Society of Internal Medicine. Ann Intern Med 2000; 132:209.
  9. Wilson KG, Chochinov HM, McPherson CJ, et al. Suffering with advanced cancer. J Clin Oncol 2007; 25:1691.
  10. Chochinov HM, Tataryn D, Clinch JJ, Dudgeon D. Will to live in the terminally ill. Lancet 1999; 354:816.
  11. Portenoy RK, Thaler HT, Kornblith AB, et al. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 1994; 3:183.
  12. Wilson KG, Chochinov HM, Skirko MG, et al. Depression and anxiety disorders in palliative cancer care. J Pain Symptom Manage 2007; 33:118.
  13. Hinton J. Which patients with terminal cancer are admitted from home care? Palliat Med 1994; 8:197.
  14. Christakis NA. Timing of referral of terminally ill patients to an outpatient hospice. J Gen Intern Med 1994; 9:314.
  15. Pelletier G, Verhoef MJ, Khatri N, Hagen N. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol 2002; 57:41.
  16. Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001; 161:1849.
  17. Tiernan E, Casey P, O'Boyle C, et al. Relations between desire for early death, depressive symptoms and antidepressant prescribing in terminally ill patients with cancer. J R Soc Med 2002; 95:386.
  18. Akechi T, Okamura H, Nishiwaki Y, Uchitomi Y. Predictive factors for suicidal ideation in patients with unresectable lung carcinoma. Cancer 2002; 95:1085.
  19. Akechi T, Okuyama T, Sugawara Y, et al. Suicidality in terminally ill Japanese patients with cancer. Cancer 2004; 100:183.
  20. Breitbart W, Rosenfeld B, Pessin H, et al. Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA 2000; 284:2907.
  21. Breitbart W. Suicide in cancer patients. Oncology (Williston Park) 1987; 1:49.
  22. Chochinov HM, Wilson KG, Enns M, et al. Desire for death in the terminally ill. Am J Psychiatry 1995; 152:1185.
  23. Breitbart W, Rosenfeld B, Gibson C, et al. Impact of treatment for depression on desire for hastened death in patients with advanced AIDS. Psychosomatics 2010; 51:98.
  24. Breitbart W. Cancer pain and suicide. In: Advances in Pain Research and Therapy, Foley KM, Bonica JJ, Ventafridda V, Callaway M (Eds), Raven Press, 1990. Vol 16, p.399.
  25. Beck AT, Kovacs M, Weissman A. Hopelessness and suicidal behavior. An overview. JAMA 1975; 234:1146.
  26. Kovacs M, Beck AT, Weissman A. Hopelessness: an indicator of suicidal risk. Suicide 1975; 5:98.
  27. Abbey JG, Rosenfeld B, Pessin H, Breitbart W. Hopelessness at the end of life: the utility of the hopelessness scale with terminally ill cancer patients. Br J Health Psychol 2006; 11:173.
  28. Lloyd-Williams M, Payne S, Reeve J, Dona RK. Thoughts of self-harm and depression as prognostic factors in palliative care patients. J Affect Disord 2014; 166:324.
  29. Emanuel EJ, Fairclough DL, Emanuel LL. Attitudes and desires related to euthanasia and physician-assisted suicide among terminally ill patients and their caregivers. JAMA 2000; 284:2460.
  30. Regier DA, Boyd JH, Burke JD Jr, et al. One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry 1988; 45:977.
  31. Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 1994; 151:979.
  32. Chochinov HM, Wilson KG, Enns M, Lander S. Prevalence of depression in the terminally ill: effects of diagnostic criteria and symptom threshold judgments. Am J Psychiatry 1994; 151:537.
  33. Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 2004; :57.
  34. McDaniel JS, Musselman DL, Porter MR, et al. Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry 1995; 52:89.
  35. Akechi T, Okuyama T, Sugawara Y, et al. Major depression, adjustment disorders, and post-traumatic stress disorder in terminally ill cancer patients: associated and predictive factors. J Clin Oncol 2004; 22:1957.
  36. Hotopf M, Chidgey J, Addington-Hall J, Ly KL. Depression in advanced disease: a systematic review Part 1. Prevalence and case finding. Palliat Med 2002; 16:81.
  37. Bukberg J, Penman D, Holland JC. Depression in hospitalized cancer patients. Psychosom Med 1984; 46:199.
  38. Evans DL, Staab JP, Petitto JM, et al. Depression in the medical setting: biopsychological interactions and treatment considerations. J Clin Psychiatry 1999; 60 Suppl 4:40.
  39. Ciaramella A, Poli P. Assessment of depression among cancer patients: the role of pain, cancer type and treatment. Psychooncology 2001; 10:156.
  40. Kathol RG, Mutgi A, Williams J, et al. Diagnosis of major depression in cancer patients according to four sets of criteria. Am J Psychiatry 1990; 147:1021.
  41. Power D, Kelly S, Gilsenan J, et al. Suitable screening tests for cognitive impairment and depression in the terminally ill--a prospective prevalence study. Palliat Med 1993; 7:213.
  42. Chochinov HM, Tataryn DJ, Wilson KG, et al. Prognostic awareness and the terminally ill. Psychosomatics 2000; 41:500.
  43. Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis 2007; 14:82.
  44. Cohen LM, Dobscha SK, Hails KC, et al. Depression and suicidal ideation in patients who discontinue the life-support treatment of dialysis. Psychosom Med 2002; 64:889.
  45. Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66:996.
  46. Lieberman A. Depression in Parkinson's disease -- a review. Acta Neurol Scand 2006; 113:1.
  47. Chwastiak L, Ehde DM, Gibbons LE, et al. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry 2002; 159:1862.
  48. Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006; 48:1527.
  49. Gibbs JS, McCoy AS, Gibbs LM, et al. Living with and dying from heart failure: the role of palliative care. Heart 2002; 88 Suppl 2:ii36.
  50. Selwyn PA, Rivard M, Kappell D, et al. Palliative care for AIDS at a large urban teaching hospital: program description and preliminary outcomes. J Palliat Med 2003; 6:461.
  51. Cook JA, Grey D, Burke J, et al. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health 2004; 94:1133.
  52. Harrison J, Maguire P. Predictors of psychiatric morbidity in cancer patients. Br J Psychiatry 1994; 165:593.
  53. Matulonis UA. End of life issues in older patients. Semin Oncol 2004; 31:274.
  54. Carroll BT, Kathol RG, Noyes R Jr, et al. Screening for depression and anxiety in cancer patients using the Hospital Anxiety and Depression Scale. Gen Hosp Psychiatry 1993; 15:69.
  55. Kathol RG, Noyes R Jr, Williams J, et al. Diagnosing depression in patients with medical illness. Psychosomatics 1990; 31:434.
  56. Levine PM, Silberfarb PM, Lipowski ZJ. Mental disorders in cancer patients: a study of 100 psychiatric referrals. Cancer 1978; 42:1385.
  57. Noyes R Jr, Kathol RG, Debelius-Enemark P, et al. Distress associated with cancer as measured by the illness distress scale. Psychosomatics 1990; 31:321.
  58. Walsh D, Donnelly S, Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 2000; 8:175.
  59. DeFlorio ML, Massie MJ. Review of depression in cancer: Gender differences. Depression 1995; 3:66.
  60. Hughes JE. Depressive illness and lung cancer. I. Depression before diagnosis. Eur J Surg Oncol 1985; 11:15.
  61. Kelsen DP, Portenoy RK, Thaler HT, et al. Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 1995; 13:748.
  62. Glover J, Dibble SL, Dodd MJ, Miaskowski C. Mood states of oncology outpatients: does pain make a difference? J Pain Symptom Manage 1995; 10:120.
  63. Chochinov HM, Wilson KG. The euthanasia debate: attitudes, practices and psychiatric considerations. Can J Psychiatry 1995; 40:593.
  64. Spiegel D, Bloom JR. Pain in metastatic breast cancer. Cancer 1983; 52:341.
  65. Wilson KG, Chochinov HM. Physician-assisted suicide. N Engl J Med 1996; 335:518.
  66. Spiegel D, Sands S, Koopman C. Pain and depression in patients with cancer. Cancer 1994; 74:2570.
  67. Boyd AD, Riba M. Depression and pancreatic cancer. J Natl Compr Canc Netw 2007; 5:113.
  68. Shakin EJ, Holland J. Depression and pancreatic cancer. J Pain Symptom Manage 1988; 3:194.
  69. Mainio A, Hakko H, Niemelä A, et al. Gender difference in relation to depression and quality of life among patients with a primary brain tumor. Eur Psychiatry 2006; 21:194.
  70. Litofsky NS, Farace E, Anderson F Jr, et al. Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery 2004; 54:358.
  71. Weitzner MA, Kanfer S, Booth-Jones M. Apathy and pituitary disease: it has nothing to do with depression. J Neuropsychiatry Clin Neurosci 2005; 17:159.
  72. Kelly WF, Checkley SA, Bender DA, Mashiter K. Cushing's syndrome and depression--a prospective study of 26 patients. Br J Psychiatry 1983; 142:16.
  73. Breitbart W. Endocrine-related psychiatric disorders. In: Handbook of Psychooncology: Psychological Care of the Patient with Cancer, Holland JC, Rowland JH (Eds), Oxford University Press, 1989. p.356.
  74. Brown JH, Paraskevas F. Cancer and depression: cancer presenting with depressive illness: an autoimmune disease? Br J Psychiatry 1982; 141:227.
  75. Patten SB, Barbui C. Drug-induced depression: a systematic review to inform clinical practice. Psychother Psychosom 2004; 73:207.
  76. Devlen J, Maguire P, Phillips P, et al. Psychological problems associated with diagnosis and treatment of lymphomas. I: Retrospective study. Br Med J (Clin Res Ed) 1987; 295:953.
  77. Devlen J, Maguire P, Phillips P, Crowther D. Psychological problems associated with diagnosis and treatment of lymphomas. II: Prospective study. Br Med J (Clin Res Ed) 1987; 295:955.
  78. Stiefel FC, Breitbart WS, Holland JC. Corticosteroids in cancer: neuropsychiatric complications. Cancer Invest 1989; 7:479.
  79. Holland J, Fasanello S, Onuma T. Psychiatric symptoms associated with L-asparaginase administration. J Psychiatr Res 1974; 10:105.
  80. Adams F, Quesada JR, Gutterman JU. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 1984; 252:938.
  81. Denicoff KD, Rubinow DR, Papa MZ, et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987; 107:293.
  82. Weddington WW Jr. Delirium and depression associated with amphotericin B. Psychosomatics 1982; 23:1076.
  83. Kelly C, Paleri V, Downs C, Shah R. Deterioration in quality of life and depressive symptoms during radiation therapy for head and neck cancer. Otolaryngol Head Neck Surg 2007; 136:108.
  84. Irwin PH, Kramer S, Diamond NH, et al. Sex differences in psychological distress during definitive radiation therapy for cancer. J Psychosoc Oncol 1986; 4:63.
  85. Sehlen S, Lenk M, Herschbach P, et al. Depressive symptoms during and after radiotherapy for head and neck cancer. Head Neck 2003; 25:1004.
  86. Kohda R, Otsubo T, Kuwakado Y, et al. Prospective studies on mental status and quality of life in patients with head and neck cancer treated by radiation. Psychooncology 2005; 14:331.
  87. Armstrong CL, Gyato K, Awadalla AW, et al. A critical review of the clinical effects of therapeutic irradiation damage to the brain: the roots of controversy. Neuropsychol Rev 2004; 14:65.
  88. Boston P, Bruce A, Schreiber R. Existential suffering in the palliative care setting: an integrated literature review. J Pain Symptom Manage 2011; 41:604.
  89. Nelson CJ, Rosenfeld B, Breitbart W, Galietta M. Spirituality, religion, and depression in the terminally ill. Psychosomatics 2002; 43:213.
  90. Andersen BL, DeRubeis RJ, Berman BS, et al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. J Clin Oncol 2014; 32:1605.
  91. Labisi O. Assessing for suicide risk in depressed geriatric cancer patients. J Psychosoc Oncol 2006; 24:43.
  92. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, 2013.
  93. Endicott J. Measurement of depression in patients with cancer. Cancer 1984; 53:2243.
  94. Block SD. Psychological issues in end-of-life care. J Palliat Med 2006; 9:751.
  95. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.
  96. Kroenke K, Spitzer RL. The PHQ-9: a new depression and diagnostic severity measure. Psychiatr Ann 2002; 32:509.
  97. Beck AT, Beck RW. Screening depressed patients in family practice. A rapid technic. Postgrad Med 1972; 52:81.
  98. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess 1996; 67:588.
  99. Chochinov HM, Wilson KG, Enns M, Lander S. "Are you depressed?" Screening for depression in the terminally ill. Am J Psychiatry 1997; 154:674.
  100. Lees N, Lloyd-Williams M. Assessing depression in palliative care patients using the visual analogue scale: a pilot study. Eur J Cancer Care (Engl) 1999; 8:220.
  101. Periyakoil VS, Kraemer HC, Noda A, et al. The development and initial validation of the Terminally Ill Grief or Depression Scale (TIGDS). Int J Methods Psychiatr Res 2005; 14:202.
  102. Lloyd-Williams M, Spiller J, Ward J. Which depression screening tools should be used in palliative care? Palliat Med 2003; 17:40.
  103. Holtom N, Barraclough J. Is the Hospital Anxiety and Depression Scale (HADS) useful in assessing depression in palliative care? Palliat Med 2000; 14:219.
  104. Lloyd-Williams M, Dennis M, Taylor F. A prospective study to compare three depression screening tools in patients who are terminally ill. Gen Hosp Psychiatry 2004; 26:384.
  105. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978; 35:837.
  106. Jefford M, Mileshkin L, Richards K, et al. Rapid screening for depression--validation of the Brief Case-Find for Depression (BCD) in medical oncology and palliative care patients. Br J Cancer 2004; 91:900.
  107. Fishman B, Pasternak S, Wallenstein SL, et al. The Memorial Pain Assessment Card. A valid instrument for the evaluation of cancer pain. Cancer 1987; 60:1151.
  108. Robinson JA, Crawford GB. Identifying palliative care patients with symptoms of depression: an algorithm. Palliat Med 2005; 19:278.
  109. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473.
  110. Berwick DM, Murphy JM, Goldman PA, et al. Performance of a five-item mental health screening test. Med Care 1991; 29:169.
  111. Thekkumpurath P, Venkateswaran C, Kumar M, Bennett MI. Screening for psychological distress in palliative care: a systematic review. J Pain Symptom Manage 2008; 36:520.
  112. Mitchell AJ. Are one or two simple questions sufficient to detect depression in cancer and palliative care? A Bayesian meta-analysis. Br J Cancer 2008; 98:1934.
  113. Mahoney J, Drinka TJ, Abler R, et al. Screening for depression: single question versus GDS. J Am Geriatr Soc 1994; 42:1006.
  114. Watkins C, Daniels L, Jack C, et al. Accuracy of a single question in screening for depression in a cohort of patients after stroke: comparative study. BMJ 2001; 323:1159.
  115. Lloyd-Williams M, Dennis M, Taylor F, Baker I. Is asking patients in palliative care, "are you depressed?" Appropriate? Prospective study. BMJ 2003; 327:372.
  116. Akechi T, Okuyama T, Sugawara Y, et al. Screening for depression in terminally ill cancer patients in Japan. J Pain Symptom Manage 2006; 31:5.
  117. Riba MB, Donovan KA, Andersen B, et al. Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019; 17:1229.
  118. Walker J, Hansen CH, Martin P, et al. Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data. Lancet Psychiatry 2014; 1:343.
  119. A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators. JAMA 1995; 274:1591.
  120. Spiegel D, Bloom JR, Yalom I. Group support for patients with metastatic cancer. A randomized outcome study. Arch Gen Psychiatry 1981; 38:527.
  121. Spiegel D, Bloom JR. Group therapy and hypnosis reduce metastatic breast carcinoma pain. Psychosom Med 1983; 45:333.
  122. Massie MJ, Holland JC, Straker N. Psychotherapeutic interventions. In: Handbook of Psychooncology: Psychological Care of the Patient with Cancer, Holland JC, Rowland JH (Eds), Oxford University Press, 1989. p.455.
  123. Holland JC, Morrow GR, Schmale A, et al. A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms. J Clin Oncol 1991; 9:1004.
  124. Fisch M. Treatment of depression in cancer. J Natl Cancer Inst Monogr 2004; :105.
  125. Ly KL, Chidgey J, Addington-Hall J, Hotopf M. Depression in palliative care: a systematic review. Part 2. Treatment. Palliat Med 2002; 16:279.
  126. Walker J, Hansen CH, Martin P, et al. Integrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): a multicentre randomised controlled trial in patients with lung cancer. Lancet Oncol 2014; 15:1168.
  127. Sheard T, Maguire P. The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses. Br J Cancer 1999; 80:1770.
  128. Newell SA, Sanson-Fisher RW, Savolainen NJ. Systematic review of psychological therapies for cancer patients: overview and recommendations for future research. J Natl Cancer Inst 2002; 94:558.
  129. Devine EC, Westlake SK. The effects of psychoeducational care provided to adults with cancer: meta-analysis of 116 studies. Oncol Nurs Forum 1995; 22:1369.
  130. Meyer TJ, Mark MM. Effects of psychosocial interventions with adult cancer patients: a meta-analysis of randomized experiments. Health Psychol 1995; 14:101.
  131. Stagg EK, Lazenby M. Best practices for the nonpharmacological treatment of depression at the end of life. Am J Hosp Palliat Care 2012; 29:183.
  132. Ciechanowski P, Wagner E, Schmaling K, et al. Community-integrated home-based depression treatment in older adults: a randomized controlled trial. JAMA 2004; 291:1569.
  133. Bruce ML, Ten Have TR, Reynolds CF 3rd, et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial. JAMA 2004; 291:1081.
  134. Wilson KG, Chochinov HM, de Faye BJ, Breitbart W. Assessment and management of depression in palliative care. In: Handbook of Psychiatry in Palliative Medicine, Chochinov HM, Breitbart W (Eds), Oxford University Press, 2000. p.2.
  135. Chochinov HM, Hack T, Hassard T, et al. Dignity therapy: a novel psychotherapeutic intervention for patients near the end of life. J Clin Oncol 2005; 23:5520.
  136. Montross L, Winters KD, Irwin SA. Dignity therapy implementation in a community-based hospice setting. J Palliat Med 2011; 14:729.
  137. Chochinov HM, Kristjanson LJ, Breitbart W, et al. Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial. Lancet Oncol 2011; 12:753.
  138. Vuksanovic D, Green HJ, Dyck M, Morrissey SA. Dignity Therapy and Life Review for Palliative Care Patients: A Randomized Controlled Trial. J Pain Symptom Manage 2017; 53:162.
  139. Martínez M, Arantzamendi M, Belar A, et al. 'Dignity therapy', a promising intervention in palliative care: A comprehensive systematic literature review. Palliat Med 2017; 31:492.
  140. Breitbart W, Rosenfeld B, Pessin H, et al. Meaning-centered group psychotherapy: an effective intervention for improving psychological well-being in patients with advanced cancer. J Clin Oncol 2015; 33:749.
  141. Breitbart W, Pessin H, Rosenfeld B, et al. Individual meaning-centered psychotherapy for the treatment of psychological and existential distress: A randomized controlled trial in patients with advanced cancer. Cancer 2018; 124:3231.
  142. Keall RM, Clayton JM, Butow PN. Therapeutic life review in palliative care: a systematic review of quantitative evaluations. J Pain Symptom Manage 2015; 49:747.
  143. Rayner L, Price A, Evans A, et al. Antidepressants for depression in physically ill people. Cochrane Database Syst Rev 2010; :CD007503.
  144. Rayner L, Price A, Evans A, et al. Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysis. Palliat Med 2011; 25:36.
  145. Qaseem A, Snow V, Denberg TD, et al. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008; 149:725.
  146. Mulrow CD, Williams JW Jr, Chiquette E, et al. Efficacy of newer medications for treating depression in primary care patients. Am J Med 2000; 108:54.
  147. Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005; 143:415.
  148. Rayner L, Price A, Hotopf M, Higginson IJ. The development of evidence-based European guidelines on the management of depression in palliative cancer care. Eur J Cancer 2011; 47:702.
  149. Burns MM, Eisendrath SJ. Dextroamphetamine treatment for depression in terminally ill patients. Psychosomatics 1994; 35:80.
  150. Olin J, Masand P. Psychostimulants for depression in hospitalized cancer patients. Psychosomatics 1996; 37:57.
  151. Macleod AD. Methylphenidate in terminal depression. J Pain Symptom Manage 1998; 16:193.
  152. Wallace AE, Kofoed LL, West AN. Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. Am J Psychiatry 1995; 152:929.
  153. Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry 2000; 61:436.
  154. Ng CG, Boks MP, Roes KC, et al. Rapid response to methylphenidate as an add-on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: a four-week, randomized, double-blinded, placebo-controlled study. Eur Neuropsychopharmacol 2014; 24:491.
  155. Fisch MJ, Loehrer PJ, Kristeller J, et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol 2003; 21:1937.
  156. Holland JC, Romano SJ, Heiligenstein JH, et al. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology 1998; 7:291.
  157. Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics. J Clin Psychopharmacol 1990; 10:48.
  158. Pearson HJ. Interaction of fluoxetine with carbamazepine. J Clin Psychiatry 1990; 51:126.
  159. Breitbart W, Passik SD. Psychiatric aspects of palliative care. In: Oxford Textbook of Palliative Medicine, Doyle D, Hanks GW, MacDonald (Eds), Oxford University Press, 1993.
  160. Preskorn SH, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol 1990; 10:88.
  161. Theobald DE, Kirsh KL, Holtsclaw E, et al. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 2002; 23:442.
  162. Thompson DS. Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. Psychosomatics 2000; 41:356.
  163. Thompson JW Jr, Ware MR, Blashfield RK. Psychotropic medication and priapism: a comprehensive review. J Clin Psychiatry 1990; 51:430.
  164. Shopsin B. Bupropion: a new clinical profile in the psychobiology of depression. J Clin Psychiatry 1983; 44:140.
  165. Cullum JL, Wojciechowski AE, Pelletier G, Simpson JS. Bupropion sustained release treatment reduces fatigue in cancer patients. Can J Psychiatry 2004; 49:139.
  166. Peck AW, Stern WC, Watkinson C. Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J Clin Psychiatry 1983; 44:197.
  167. Dessain EC, Schatzberg AF, Woods BT, Cole JO. Maprotiline treatment in depression. A perspective on seizures. Arch Gen Psychiatry 1986; 43:86.
  168. van Heeringen K, Zivkov M. Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. Br J Psychiatry 1996; 169:440.
  169. Preskorn SH, Burke M. Somatic therapy for major depressive disorder: selection of an antidepressant. J Clin Psychiatry 1992; 53 Suppl:5.
  170. van Marwijk H, Allick G, Wegman F, et al. Alprazolam for depression. Cochrane Database Syst Rev 2012; :CD007139.
  171. Fernandez F, Adams F, Holmes VF, et al. Methylphenidate for depressive disorders in cancer patients. An alternative to standard antidepressants. Psychosomatics 1987; 28:455.
  172. Webster L, Andrews M, Stoddard G. Modafinil treatment of opioid-induced sedation. Pain Med 2003; 4:135.
  173. Rozans M, Dreisbach A, Lertora JJ, Kahn MJ. Palliative uses of methylphenidate in patients with cancer: a review. J Clin Oncol 2002; 20:335.
  174. Centeno C, Sanz A, Cuervo MA, et al. Multicentre, double-blind, randomised placebo-controlled clinical trial on the efficacy of methylphenidate on depressive symptoms in advanced cancer patients. BMJ Support Palliat Care 2012; 2:328.
  175. Stiefel F, Die Trill M, Berney A, et al. Depression in palliative care: a pragmatic report from the Expert Working Group of the European Association for Palliative Care. Support Care Cancer 2001; 9:477.
  176. Zanicotti CG, Perez D, Glue P. Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. J Palliat Med 2012; 15:400.
  177. Stefanczyk-Sapieha L, Oneschuk D, Demas M. Intravenous ketamine "burst" for refractory depression in a patient with advanced cancer. J Palliat Med 2008; 11:1268.
  178. Yang C, Zhou ZQ, Yang JJ. Be prudent of ketamine in treating resistant depression in patients with cancer. J Palliat Med 2011; 14:537.
  179. Thangathurai D, Roby J, Roffey P. Treatment of resistant depression in patients with cancer with low doses of ketamine and desipramine. J Palliat Med 2010; 13:235.
  180. Kollmar R, Markovic K, Thürauf N, et al. Ketamine followed by memantine for the treatment of major depression. Aust N Z J Psychiatry 2008; 42:170.
  181. Irwin SA, Iglewicz A. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J Palliat Med 2010; 13:903.
  182. Iglewicz A, Morrison K, Nelesen RA, et al. Ketamine for the treatment of depression in patients receiving hospice care: a retrospective medical record review of thirty-one cases. Psychosomatics 2015; 56:329.
  183. Jafarinia M, Afarideh M, Tafakhori A, et al. Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial. J Affect Disord 2016; 204:1.
  184. Singh JB, Fedgchin M, Daly EJ, et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. Am J Psychiatry 2016; 173:816.
  185. Ross S, Franco S, Reiff C, Agin-Liebes G. Psilocybin. In: Handbook of Medical Hallucinogens, Grob CS, Grigsby J (Eds), The Guilford Press, 2021. p.181.
  186. Ross S. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Int Rev Psychiatry 2018; 30:317.
  187. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 2016; 30:1181.
  188. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 2016; 30:1165.
  189. Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 2011; 68:71.
  190. Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2021; 78:481.
  191. Anderson BT, Danforth A, Daroff PR, et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine 2020; 27:100538.
  192. Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 2016; 3:619.
  193. Agin-Liebes GI, Malone T, Yalch MM, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol 2020; 34:155.
  194. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med 2021; 384:1402.
  195. Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl) 2018; 235:399.
  196. Ross S, Agin-Liebes G, Lo S, et al. Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. ACS Pharmacol Transl Sci 2021; 4:553.
  197. Multidisciplinary Association for Psychedelic Studies. Press release: FDA agrees to expanded access program for MDMA-assisted psychotherapy for PTSD. 2020. Available at: https://maps.org/news/media/8008-press-release-fda-agrees-to-expanded-access-program-for-mdma-assisted-psychotherapy-for-ptsd (Accessed on September 22, 2021).
  198. Bonsignore A, Barranco R, Morando A, et al. MDMA Induced Cardio-toxicity and Pathological Myocardial Effects: A Systematic Review of Experimental Data and Autopsy Findings. Cardiovasc Toxicol 2019; 19:493.
  199. Guerreiro DF, Carmo AL, da Silva JA, et al. [Club drugs]. Acta Med Port 2011; 24:739.
  200. Rogers G, Elston J, Garside R, et al. The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Health Technol Assess 2009; 13:iii.
  201. Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 2021; 27:1025.
  202. Massie MJ, Holland JC. Depression and the cancer patient. J Clin Psychiatry 1990; 51 Suppl:12.
Topic 2205 Version 58.0

References

1 : Neuropsychiatric syndromes and psychological symptoms in patients with advanced cancer.

2 : Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs.

3 : A survey of antidepressant prescribing in the terminally ill.

4 : Desire for hastened death, cancer pain and depression: report of a longitudinal observational study.

5 : Depressive symptoms in advanced cancer. Part 2. Depression over time; the role of the palliative care professional.

6 : Trajectory of performance status and symptom scores for patients with cancer during the last six months of life.

7 : Oncologists' recognition of depression in their patients with cancer.

8 : Assessing and managing depression in the terminally ill patient. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians - American Society of Internal Medicine.

9 : Suffering with advanced cancer.

10 : Will to live in the terminally ill.

11 : Symptom prevalence, characteristics and distress in a cancer population.

12 : Depression and anxiety disorders in palliative cancer care.

13 : Which patients with terminal cancer are admitted from home care?

14 : Timing of referral of terminally ill patients to an outpatient hospice.

15 : Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues.

16 : Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure.

17 : Relations between desire for early death, depressive symptoms and antidepressant prescribing in terminally ill patients with cancer.

18 : Predictive factors for suicidal ideation in patients with unresectable lung carcinoma.

19 : Suicidality in terminally ill Japanese patients with cancer.

20 : Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer.

21 : Suicide in cancer patients.

22 : Desire for death in the terminally ill.

23 : Impact of treatment for depression on desire for hastened death in patients with advanced AIDS.

24 : Impact of treatment for depression on desire for hastened death in patients with advanced AIDS.

25 : Hopelessness and suicidal behavior. An overview.

26 : Hopelessness: an indicator of suicidal risk.

27 : Hopelessness at the end of life: the utility of the hopelessness scale with terminally ill cancer patients.

28 : Thoughts of self-harm and depression as prognostic factors in palliative care patients.

29 : Attitudes and desires related to euthanasia and physician-assisted suicide among terminally ill patients and their caregivers.

30 : One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites.

31 : The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey.

32 : Prevalence of depression in the terminally ill: effects of diagnostic criteria and symptom threshold judgments.

33 : Prevalence of depression in patients with cancer.

34 : Depression in patients with cancer. Diagnosis, biology, and treatment.

35 : Major depression, adjustment disorders, and post-traumatic stress disorder in terminally ill cancer patients: associated and predictive factors.

36 : Depression in advanced disease: a systematic review Part 1. Prevalence and case finding.

37 : Depression in hospitalized cancer patients.

38 : Depression in the medical setting: biopsychological interactions and treatment considerations.

39 : Assessment of depression among cancer patients: the role of pain, cancer type and treatment.

40 : Diagnosis of major depression in cancer patients according to four sets of criteria.

41 : Suitable screening tests for cognitive impairment and depression in the terminally ill--a prospective prevalence study.

42 : Prognostic awareness and the terminally ill.

43 : The prevalence of symptoms in end-stage renal disease: a systematic review.

44 : Depression and suicidal ideation in patients who discontinue the life-support treatment of dialysis.

45 : Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

46 : Depression in Parkinson's disease -- a review.

47 : Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample.

48 : Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes.

49 : Living with and dying from heart failure: the role of palliative care.

50 : Palliative care for AIDS at a large urban teaching hospital: program description and preliminary outcomes.

51 : Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women.

52 : Predictors of psychiatric morbidity in cancer patients.

53 : End of life issues in older patients.

54 : Screening for depression and anxiety in cancer patients using the Hospital Anxiety and Depression Scale.

55 : Diagnosing depression in patients with medical illness.

56 : Mental disorders in cancer patients: a study of 100 psychiatric referrals.

57 : Distress associated with cancer as measured by the illness distress scale.

58 : The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients.

59 : Review of depression in cancer: Gender differences

60 : Depressive illness and lung cancer. I. Depression before diagnosis.

61 : Pain and depression in patients with newly diagnosed pancreas cancer.

62 : Mood states of oncology outpatients: does pain make a difference?

63 : The euthanasia debate: attitudes, practices and psychiatric considerations.

64 : Pain in metastatic breast cancer.

65 : Physician-assisted suicide.

66 : Pain and depression in patients with cancer.

67 : Depression and pancreatic cancer.

68 : Depression and pancreatic cancer.

69 : Gender difference in relation to depression and quality of life among patients with a primary brain tumor.

70 : Depression in patients with high-grade glioma: results of the Glioma Outcomes Project.

71 : Apathy and pituitary disease: it has nothing to do with depression.

72 : Cushing's syndrome and depression--a prospective study of 26 patients.

73 : Cushing's syndrome and depression--a prospective study of 26 patients.

74 : Cancer and depression: cancer presenting with depressive illness: an autoimmune disease?

75 : Drug-induced depression: a systematic review to inform clinical practice.

76 : Psychological problems associated with diagnosis and treatment of lymphomas. I: Retrospective study.

77 : Psychological problems associated with diagnosis and treatment of lymphomas. II: Prospective study.

78 : Corticosteroids in cancer: neuropsychiatric complications.

79 : Psychiatric symptoms associated with L-asparaginase administration.

80 : Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer.

81 : The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.

82 : Delirium and depression associated with amphotericin B.

83 : Deterioration in quality of life and depressive symptoms during radiation therapy for head and neck cancer.

84 : Sex differences in psychological distress during definitive radiation therapy for cancer

85 : Depressive symptoms during and after radiotherapy for head and neck cancer.

86 : Prospective studies on mental status and quality of life in patients with head and neck cancer treated by radiation.

87 : A critical review of the clinical effects of therapeutic irradiation damage to the brain: the roots of controversy.

88 : Existential suffering in the palliative care setting: an integrated literature review.

89 : Spirituality, religion, and depression in the terminally ill.

90 : Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation.

91 : Assessing for suicide risk in depressed geriatric cancer patients.

92 : Assessing for suicide risk in depressed geriatric cancer patients.

93 : Measurement of depression in patients with cancer.

94 : Psychological issues in end-of-life care.

95 : The PHQ-9: validity of a brief depression severity measure.

96 : The PHQ-9: a new depression and diagnostic severity measure

97 : Screening depressed patients in family practice. A rapid technic.

98 : Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients.

99 : "Are you depressed?" Screening for depression in the terminally ill.

100 : Assessing depression in palliative care patients using the visual analogue scale: a pilot study.

101 : The development and initial validation of the Terminally Ill Grief or Depression Scale (TIGDS).

102 : Which depression screening tools should be used in palliative care?

103 : Is the Hospital Anxiety and Depression Scale (HADS) useful in assessing depression in palliative care?

104 : A prospective study to compare three depression screening tools in patients who are terminally ill.

105 : A diagnostic interview: the schedule for affective disorders and schizophrenia.

106 : Rapid screening for depression--validation of the Brief Case-Find for Depression (BCD) in medical oncology and palliative care patients.

107 : The Memorial Pain Assessment Card. A valid instrument for the evaluation of cancer pain.

108 : Identifying palliative care patients with symptoms of depression: an algorithm.

109 : The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

110 : Performance of a five-item mental health screening test.

111 : Screening for psychological distress in palliative care: a systematic review.

112 : Are one or two simple questions sufficient to detect depression in cancer and palliative care? A Bayesian meta-analysis.

113 : Screening for depression: single question versus GDS.

114 : Accuracy of a single question in screening for depression in a cohort of patients after stroke: comparative study.

115 : Is asking patients in palliative care, "are you depressed?" Appropriate? Prospective study.

116 : Screening for depression in terminally ill cancer patients in Japan.

117 : Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

118 : Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data.

119 : A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators.

120 : Group support for patients with metastatic cancer. A randomized outcome study.

121 : Group therapy and hypnosis reduce metastatic breast carcinoma pain.

122 : Group therapy and hypnosis reduce metastatic breast carcinoma pain.

123 : A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms.

124 : Treatment of depression in cancer.

125 : Depression in palliative care: a systematic review. Part 2. Treatment.

126 : Integrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): a multicentre randomised controlled trial in patients with lung cancer.

127 : The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses.

128 : Systematic review of psychological therapies for cancer patients: overview and recommendations for future research.

129 : The effects of psychoeducational care provided to adults with cancer: meta-analysis of 116 studies.

130 : Effects of psychosocial interventions with adult cancer patients: a meta-analysis of randomized experiments.

131 : Best practices for the nonpharmacological treatment of depression at the end of life.

132 : Community-integrated home-based depression treatment in older adults: a randomized controlled trial.

133 : Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial.

134 : Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial.

135 : Dignity therapy: a novel psychotherapeutic intervention for patients near the end of life.

136 : Dignity therapy implementation in a community-based hospice setting.

137 : Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial.

138 : Dignity Therapy and Life Review for Palliative Care Patients: A Randomized Controlled Trial.

139 : 'Dignity therapy', a promising intervention in palliative care: A comprehensive systematic literature review.

140 : Meaning-centered group psychotherapy: an effective intervention for improving psychological well-being in patients with advanced cancer.

141 : Individual meaning-centered psychotherapy for the treatment of psychological and existential distress: A randomized controlled trial in patients with advanced cancer.

142 : Therapeutic life review in palliative care: a systematic review of quantitative evaluations.

143 : Antidepressants for depression in physically ill people.

144 : Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysis.

145 : Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians.

146 : Efficacy of newer medications for treating depression in primary care patients.

147 : Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder.

148 : The development of evidence-based European guidelines on the management of depression in palliative cancer care.

149 : Dextroamphetamine treatment for depression in terminally ill patients.

150 : Psychostimulants for depression in hospitalized cancer patients.

151 : Methylphenidate in terminal depression.

152 : Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients.

153 : Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial.

154 : Rapid response to methylphenidate as an add-on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: a four-week, randomized, double-blinded, placebo-controlled study.

155 : Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group.

156 : A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer.

157 : Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.

158 : Interaction of fluoxetine with carbamazepine.

159 : Interaction of fluoxetine with carbamazepine.

160 : Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring.

161 : An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms.

162 : Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology.

163 : Psychotropic medication and priapism: a comprehensive review.

164 : Bupropion: a new clinical profile in the psychobiology of depression.

165 : Bupropion sustained release treatment reduces fatigue in cancer patients.

166 : Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion.

167 : Maprotiline treatment in depression. A perspective on seizures.

168 : Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin.

169 : Somatic therapy for major depressive disorder: selection of an antidepressant.

170 : Alprazolam for depression.

171 : Methylphenidate for depressive disorders in cancer patients. An alternative to standard antidepressants.

172 : Modafinil treatment of opioid-induced sedation.

173 : Palliative uses of methylphenidate in patients with cancer: a review.

174 : Multicentre, double-blind, randomised placebo-controlled clinical trial on the efficacy of methylphenidate on depressive symptoms in advanced cancer patients.

175 : Depression in palliative care: a pragmatic report from the Expert Working Group of the European Association for Palliative Care.

176 : Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer.

177 : Intravenous ketamine "burst" for refractory depression in a patient with advanced cancer.

178 : Be prudent of ketamine in treating resistant depression in patients with cancer.

179 : Treatment of resistant depression in patients with cancer with low doses of ketamine and desipramine.

180 : Ketamine followed by memantine for the treatment of major depression.

181 : Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care.

182 : Ketamine for the treatment of depression in patients receiving hospice care: a retrospective medical record review of thirty-one cases.

183 : Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial.

184 : A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.

185 : A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.

186 : Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress.

187 : Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

188 : Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.

189 : Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.

190 : Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.

191 : Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study.

192 : Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

193 : Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.

194 : Trial of Psilocybin versus Escitalopram for Depression.

195 : Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.

196 : Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer.

197 : Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer.

198 : MDMA Induced Cardio-toxicity and Pathological Myocardial Effects: A Systematic Review of Experimental Data and Autopsy Findings.

199 : [Club drugs].

200 : The harmful health effects of recreational ecstasy: a systematic review of observational evidence.

201 : MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.

202 : Depression and the cancer patient.